IFNG and viral pneumonia: Myasnikov and collaborators conducted a randomized study including patients with moderate COVID-19 infection, aiming to assess the effect of subcutaneous administration of IFN-γ (500,000 IU, s/c, daily, once a day, for five days) in patients with viral pneumonia on the changes in vital signs and the duration of hospital stay.